Recruitment of dendritic cells using 'find-me' signaling microparticles for personalized cancer immunotherapy

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Therapeutic cancer vaccines aim to activate cytotoxic T cells for personalized immunotherapy.
• Current cancer vaccines face limitations due to low immunogenicity and poor antigen presentation by dendritic cells (DCs).

Purpose of the Study:

• To develop 'find-me' signaling polymeric microparticles (F-PMs) that enhance DC recruitment and antigen presentation for improved cancer vaccines.
• To evaluate the efficacy of F-PMs in stimulating antitumor immune responses in preclinical models.

Main Methods:

• F-PMs were engineered to carry tumor lysate as an antigen.
• Subcutaneous injection of F-PMs into tumor-bearing mice.
• Assessment of DC maturation and recruitment in tumor-draining lymph nodes.
• Evaluation of CD8+ cytotoxic T cell enrichment in the tumor microenvironment, particularly when combined with immune checkpoint inhibitors.

Main Results:

• F-PMs significantly increased mature DCs in tumor-draining lymph nodes via adenosine triphosphate (ATP)-induced chemotaxis.
• This DC recruitment led to high antitumor efficacy.
• Co-administration with an immune checkpoint inhibitor resulted in remarkable enrichment of CD8+ cytotoxic T cells in the tumor microenvironment.

Conclusions:

• F-PMs effectively recruit DCs and facilitate antigen presentation, overcoming key limitations of traditional cancer vaccines.
• F-PMs elicit a robust antitumor immune response, demonstrating potential as a therapeutic option for cancer treatment.
• The combination of F-PMs with immune checkpoint inhibitors shows promise for enhancing T cell-mediated antitumor immunity.